Large Cell Neuroendocrine Carcinoma of the Ampulla of Vater
Context Large cell neuroendocrine carcinomas of the ampulla of Vater are rare and confer a very poor prognosis despite aggressive therapy. There are few case reports of large cell neuroendocrine carcinomas of the ampulla of Vater in the literature and to date no studies have been done to establish optimal management. We describe a pooled case series from published reports of neuroendocrine carcinomas of the ampulla of Vater including a case which presented to our institution. Methods A narrative review was undertaken including all published English case reports of large cell neuroendocrine carcinomas of the ampulla of Vater. Our primary outcome was to determine the overall survival. Results Twenty cases of large cell neuroendocrine carcinomas of the ampulla of Vater were identified. Seventy-six percent of patients were reported to have died of disease with a mean survival of 11.8 months. Twenty percent of the tumours were associated with an adenoma. The approximate median survivals were 15 months for those with an associated adenoma and 11 months without. Conclusions This pooled analysis demonstrates both the rarity and poor prognosis of large cell neuroendocrine carcinomas of the ampulla of Vater. Although surgical resection is the mainstay of treatment, we review common adjuvant chemotherapy regimes. Prognosis may be improved when these tumours are associated with adenomas, however, further studies are needed.
Image: Circumferential fleshy ulcerated tumour.
Selvakumar E, Vimalraj V, Rajendran S, Balachandar TG, Kannon DG, Jeswanth S, et al. Large cell neuroendocrine carcinoma of the ampulla of Vater. Hepatobiliary Pancreat Dis Int 2006; 5:465-7. [PMID 16911952].
Albores-Saavedra J, Hart A, Chable-Montero F, Henson DE. Carcinoids and high-grade neuroendocrine carcinomas of the ampulla of Vater: a comparative analysis of 139 cases from the surveillance, epidemiology and end results program – a population based study. Arch Pathol Lab Med 2010; 134:1692-6. [PMID 21043824].
Cavazza A, Gallo M, Valcavi R, De Marco L, Gardini G: Large cell neuroendocrine carcinoma of the ampulla of Vater. Arch Pathol Lab Med 2003; 127:221-3. [PMID 12562240].
Shu TW, Lin CW, Lin SP, Lin CH, Wei CK, Yin WY et al. High-grade large cell neuroendocrine carcinoma concomitant with tubulovillous adenoma of the ampulla of Vater – a case report. Tzu Chi Med J 2006; 18:315-318.
Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 2011; 8: 54-64. [PMID 21808296].
Rindi G. The ENETS guidelines: the new TNM classification system. Tumori, 2010; 96:806-9. [PMID 21302636].
Liszka L, Pajak J, Mrowiec S, Zielinska-Pajak E, Golka D, Lampe P. Discrepancies between two alternative staging systems (European Neuroendocrine Tumor Society 2006 and American Joint Committee on Cancer/Union for International Cancer Control 2010) of neuroendocrine neoplasms of the pancreas. A study of 50 cases. Pathol Res Pract 2011; 207:220-4. [PMID 21354717].
Selvakumar E, Rajendran S, Balachandar TG, Kannan DG, Jeswanth S, Ravichandran P, et al. Neuroendocrine carcinoma of the ampulla of Vater: a clinicopathologic evaluation. Hepatobiliary Pancreat Dis Int 2008; 7: 422-425. [PMID 18693180].
Nassar H, Albores-Saavedra J, Klimstra DS. High-grade neuroendocrine carcinoma of the ampulla of Vater: a clinicopathological and immunohistochemical analysis of 14 cases. Am J Surg Pathol 2005; 29: 588-94. [PMID 15832081].
Stojsic Z, Brasanac D, Bilanovic D, Mitrovic O, Stevanovic R, Boricic I. Large-cell neuroendocrine carcinoma of ampulla of Vater. Med Oncol 2010; 27:1144-8. [PMID 19898974].
Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, et al. Centre for Evidence Based Medicine: Levels of Evidence. Available from www.cebm.net. March 2009.
Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Niemen L, et al. Neuroendocrine tumours of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991; 15:529-553. [PMID 1709558].
Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and it’s separation from typical carcinoid. Am J Surg Pathol 1998; 22:934-44. [PMID 9706973].
World Health Organisation Histological Typing of Lung and Pleural Tumours. 3rd edit. 1999 Springer Germany.
Sunrose Y, Ogawa T, Itoh H, Andoh T, Tomizawa N, Tanaka T, et al. Large cell neuroendocrine carcinoma of the ampulla of Vater with adenocarcinoma and squamous cell carcinoma components. Jpn J Clin Oncol 2011; 41: 434-9. [PMID 20947928].
Liu SH, Tsay SH. Coexistance of large cell neuroendocrine carcinoma and adenocarcinoma of the ampulla of Vater. J Chin Med Assoc 2008; 71:536-540. [PMID 18955190].
Gornals J, Varas M, Catala I, Maisterra S, Pons C, Bargallo D, et al. Definitive diagnosis of neuroendocrine tumours using fine-needle aspiration-puncture guided by endoscopic ultrasonography. Rev Esp Enferm Dig 2001; 103:123-8. [PMID 21434714].
Hatzitheoklitos E, Buchler MW, Friess H, Poch B, Ebert M, Mohr W, et al. Carcinoid of the ampulla of Vater. Clinical characteristics and morphological features. Cancer 1994; 73:1580-88. [PMID 8156484].
Hartel M, Wente MN, Bergmann F, Schmidt J, Buchler MW, Friess H. Large cell neuroendocrine carcinoma of the major duodenal papilla: case report. Gastrointest Endosc 2004; 60:838-41. [PMID 15557973].
Kang SP, Saif MW. Ampullary and Periampullary Tumors: Translational Efforts to Meet a Challenge in Diagnosis and Treatment. JOP. J Pancreas (Online) 2011; 12:123-125. [PMID 21386636].
Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA et al. The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas. Pancreas 2010; 39:799-800. [PMID 20664477].
Moertel CG, Kvols LK, O’Connell MJ et al. Treatment of neuroendocrine carcinomas with combined etposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68:227-232. [PMID 1712661].
Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Pulmonary Large Cell Neuroendocrine Carcinoma: Its Place in the Spectrum of Pulmonary Carcinoma. Ann Thorac Surg 2007; 84:702-7. [PMID 17643676].
Hage R, Seldenrijk K, de Bruin P, van Swieten H, van den Bosch J. Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardiothorac Surg 2003; 23:457-60. [PMID 12694759].
Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA, Miller JI. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 2001; 119:14-8. [PMID 11157578].
Kozuki T, Fujimoto N, Ueoka H, et al. Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. J Cancer Res Clin Oncol 2005; 131:147-51. [PMID 15538626].
Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plockinger U. Multimodal management of neuroendocrine liver metastases. HPB 2010; 12:361-379. [PMID 20662787].
Harring TR, Nguyen TN, Goss JA, O’Mahony CA. Treatment of liver metastases in patients with neuroendocrine tumors: A comprehensive review. Int J Hepatol 2011. [PMID 22013537].
Cheng SP, Yang TL, Chang KM, Liu CL. Large cell neuroendocrine carcinoma of the ampulla of Vater with glandular differentiation. J Clinical Pathol 2004; 57:1098-100. [PMID 15452169].
Huang SS, Jan YJ, Cheng SB, Yeh DC, Wu CC, Liu TJ, P’eng FK. Large cell neuroendocrine carcinoma of the ampulla of Vater: Report of a case. Surg Today 2006; 36:1032-5. [PMID 17072731].
Copyright (c) 2014 Rachel E Beggs, Michael E Kelly, Omer Eltayeb, Paul Crotty, Ray McDermott, Paul F Ridgway
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.